Hepatitis B cirrhosis
Conditions
Interventions
Alone group:Treated with nucleoside (acid) analogues
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Cirrhosis patients with chronic HBV infection based on diagnostic criteria of 2015 China clinical practice guidelines of chronic hepatitis B (updated); 2. Males or females with age from 18 to 65 years old, capable of signing the informed consent; 3. Persistently positive HBsAg for more than 6 months (HBV DNA 2; 5. FibroTouch: ALT and total bilirubin are normal which LSM>=12.2KPa;Total bilirubin is normal and didn't antivirus treatment which LSM>=17.5KPa;Total bilirubin is abnormal which LSM>=29.2KPa; 6. Compensatory phase cirrhosis.;Inclusion criteria: 1. Cirrhosis patients with chronic HBV infection based on diagnostic criteria of 2015 China clinical practice guidelines of chronic hepatitis B (updated); 2. Males or females with age from 18 to 65 years old, capable of signing the informed consent; 3. Persistently positive HBsAg for more than 6 months (HBV DNA 2; 5. FibroTouch: ALT and total bilirubin are normal which LSM>=12.2KPa;Total bilirubin is normal and didn't antivirus treatment which LSM>=17.5KPa;Total bilirubin is abnormal which LSM>=29.2KPa; 6. Compensatory phase cirrhosis.
Exclusion criteria
Exclusion criteria: 1. Abdominal ultrasonography or CT indicate hepatocellular carcinoma; 2. Liver failure; 3. Decompensated cirrhosis; 4. Coinfection by hepatitis B virus, hepatitis C virus(Hepatitis C RNA positive), hepatitis D virus and human immunodeficiency virus (HIV) positive patients; 5. Suffered from drug-induced hepatitis, alcoholic liver disease, autoimmune hepatic disease and inherited metabolic liver disorders; 6. Combination with carcinoma, severe cardiopulmonary disease, ?connective tissue disease and organ transplantation patients; 7. Treating with nucleoside (acid) analogues before inclusion; 8. Poor compliance or information missing which may affect efficacy and safety.;Exclusion criteria: 1. Abdominal ultrasonography or CT indicate hepatocellular carcinoma; 2. Liver failure; 3. Decompensated cirrhosis; 4. Coinfection by hepatitis B virus, hepatitis C virus(Hepatitis C RNA positive), hepatitis D virus and human immunodeficiency virus (HIV) positive patients; 5. Suffered from drug-induced hepatitis, alcoholic liver disease, autoimmune hepatic disease and inherited metabolic liver disorders; 6. Combination with carcinoma, severe cardiopulmonary disease, ?connective tissue disease and organ transplantation patients; 7. Treating with nucleoside (acid) analogues before inclusion; 8. Poor compliance or information missing which may affect efficacy and safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV-DNA;AFP;hepatic decompensation rate;liver cancer rate;LSM;APRI score;;HBV-DNA;AFP;hepatic decompensation rate;liver cancer rate;LSM;APRI score; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBsAg rate of decline;serum alanine aminotransferase;platelet count;Width of portal vein trunk;Spleen size;The extent of esophageal varices by gastroscopy;;HBsAg rate of decline;serum alanine aminotransferase;platelet count;Width of portal vein trunk;Spleen size;The extent of esophageal varices by gastroscopy; | — |
Countries
China
Contacts
Public ContactLihua SUN;Lihua SUN ;
First Affiliated Hospital of Xinjiang Medical University ;First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed